Securities Class Action Filed Against Zoetis Over Companion‑Animal Drug Claims

Plaintiffs say recent earnings disclosures revealed weakening sales and competitive losses that hurt investors and could prompt a lead‑plaintiff fight under federal law.

Overview

A class action complaint was filed in the Southern District of New York on Thursday by the City of Ann Arbor Retiree Health Care Benefit Plan & Trust against Zoetis Inc. and certain executives alleging securities law violations.
The suit says company statements overstated veterinarian adoption and market position for key products and that Librela adoption slowed after FDA safety warnings about serious neurological effects in dogs.
Plaintiffs allege Simparica Trio lost share to a lower‑priced competitor and that Apoquel and Cytopoint faced new rival dermatology treatments, and they tie those problems to stepped declines in Zoetis’ stock after earnings reports.
The complaint cites quarterly disclosures on Aug. 5, 2025; Nov. 4, 2025; Feb. 12, 2026; and May 7, 2026 as revealing worsening trends and says the May 7 report preceded a more than 21% drop in the share price.
Multiple investor‑rights firms are soliciting clients to seek lead‑plaintiff status and investors have until July 27, 2026 to move for appointment; no class has been certified and the allegations remain unproven.